TRPC4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Zerencotrep (SCHEMBL16027694)	1.00	2/20
SCHEMBL16027656	0.88	2/20
SCHEMBL16027988	0.88	2/20
SCHEMBL16027987	0.84	2/20
SCHEMBL16027682	0.84	2/20
SCHEMBL16027655	0.83	2/20
SCHEMBL16028006	0.82	2/20
SCHEMBL16027658	0.81	2/20
SCHEMBL16027999	0.81	2/20
SCHEMBL16027671	0.81	2/20
SCHEMBL16027664	0.79	2/20
SCHEMBL16027679	0.79	2/20
SCHEMBL16027842	0.78	2/20
SCHEMBL16027807	0.78	2/20
SCHEMBL16027717	0.77	2/20
SCHEMBL16027934	0.76	2/20
SCHEMBL16027677	0.74	2/20
SCHEMBL16027663	0.74	2/20
SCHEMBL16027846	0.74	2/20
SCHEMBL16027643	0.73	2/20

Clinical trials — most relevant to TRPC4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls	PHASE4	COMPLETED
The Re-Prosper HF Study	PHASE2/PHASE3	COMPLETED
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction	PHASE2	ACTIVE_NOT_RECRUITING
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.	PHASE2	NOT_YET_RECRUITING
TRPM8 Activators for Peripheral Neuropathy	PHASE2	ACTIVE_NOT_RECRUITING
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases	PHASE1	COMPLETED
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC	PHASE1	COMPLETED
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8	EARLY_PHASE1	COMPLETED
Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3	EARLY_PHASE1	COMPLETED
Menthol Stimulation of Brown Adipose Tissue in Humans: Aim 1	EARLY_PHASE1	RECRUITING
The Natural History of TRPV4 Neuropathy	nan	RECRUITING
Relationship Between Polymorphisms of TRPV1 and KCC2 Gene in Children With Febrile Seizures	nan	COMPLETED
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.	nan	COMPLETED
Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children	nan	COMPLETED
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin	nan	ENROLLING_BY_INVITATION
Dissecting the Heterogeneity of Oral Cancer Pain	nan	UNKNOWN
Neurogenic Mechanisms in Burning Mouth Syndrome	nan	COMPLETED
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis	nan	UNKNOWN
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy	nan	ENROLLING_BY_INVITATION
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis	nan	UNKNOWN
Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain	nan	RECRUITING
Visual Activity Evoked by Infrared in Humans After Dark Adaptation	nan	COMPLETED
Affective Touch, Hedonia and Suicidal Behavior	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Trigeminal Endonasal Perception: A Predictor for Septoplasty Outcome	nan	COMPLETED
An Investigation Into the Mechanism of Inhalation Cough Challenge	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TRPC4 binder may also engage these)

Protein	Name	Similarity
Q9QUQ5	—	1.000	Q9QUQ5 →
P79100	—	1.000	P79100 →
O35119	—	1.000	O35119 →
Q9MYV9	—	1.000	Q9MYV9 →
TRPC5	Short transient receptor potential channel 5	1.000	landscape →
Q9QX29	—	1.000	Q9QX29 →
O62852	—	1.000	O62852 →
P34586	—	1.000	P34586 →
P48994	—	0.999	P48994 →
Q61056	—	0.999	Q61056 →
TRPC1	Short transient receptor potential channel 1	0.999	landscape →
P19334	—	0.998	P19334 →
Q704Y3	—	0.996	Q704Y3 →
TRPV1	Transient receptor potential cation channel subfamily V member 1	0.995	landscape →
Q9QX01	—	0.994	Q9QX01 →
Q9VJJ7	—	0.994	Q9VJJ7 →
O18784	—	0.994	O18784 →
Q6R5A3	—	0.994	Q6R5A3 →
Q6RX08	—	0.993	Q6RX08 →
A0A1D5PXA5	—	0.992	A0A1D5PXA5 →
Q8K424	—	0.992	Q8K424 →
Q9ERZ8	—	0.992	Q9ERZ8 →
Q9EPK8	—	0.992	Q9EPK8 →
Q5RCN4	—	0.992	Q5RCN4 →
TRPV3	Transient receptor potential cation channel subfamily V member 3	0.991	landscape →
O60353	—	0.991	O60353 →
Q9TUN9	—	0.991	Q9TUN9 →
Q80TL1	—	0.990	Q80TL1 →
Q8WMU5	—	0.990	Q8WMU5 →
Q18297	—	0.990	Q18297 →